| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 55,416 | 6,710 |
| Proceeds from issuance of common stock | 29,059 | 5,318 |
| Employee taxes paid related to net share settlement of equity awards | 4,198 | 3,387 |
| Payment of contingent consideration | 24,257 | 22,395 |
| Net cash provided by financing activities | 604 | -20,464 |
| Net change in cash, cash equivalents, and restricted cash | 83,490 | 75,380 |
| Cash and cash equivalents at beginning of period | 69,331 | - |
| Cash and cash equivalents at end of period | 152,821 | - |
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)